WILMINGTON, DE / ACCESSWIRE / December 20, 2019 / Rigrodsky & Long, P.A.:

Do you own shares of TiVo Corporation (NASDAQ GS:TIVO)?
Did you purchase any of your shares prior to December 19, 2019?
Do you think the proposed merger is fair?
Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors TiVo Corporation ("TiVo" or the "Company") (NASDAQ GS: TIVO) regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to merge with Xperi Corporation ("Xperi") (NASDAQ GS:XPER) in a transaction valued at approximately $3 billion. Under the terms of the agreement, shareholders of TiVo will receive 0.455 shares of Xperi for each share of TiVo they own. Upon completion of the transaction, shareholders of Xperi will own approximately 46.5% of the combined company and TiVo shareholders will own approximately 53.5%.

If you own common stock of TiVo and purchased any shares before December 19, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at info@rl-legal.com, or at https://www.rigrodskylong.com/offices-contact.

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT:

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com
http://www.rigrodskylong.com

SOURCE: Rigrodsky & Long, P.A.

ReleaseID: 570804

SAN FRANCISCO, CA / ACCESSWIRE / December 20, 2019 / The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action that has been filed on behalf of investors who purchased or otherwise acquired the stock of iRobot Corporation ("iRobot" or the "Company") (NASDAQ:IRBT) between November 21, 2016 and October 22, 2019, inclusive of (The "Class Period").

If you purchased or otherwise acquired the common stock of iRobot during the Class Period, you may move the Court for appointment as lead plaintiff by no later than December 23, 2019. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the actions.

iRobot investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

iRobot is a global consumer robot company that designs and builds robots to assist with household tasks. iRobot's most popular product is its Roomba line of autonomous robotic vacuum cleaners.

The actions allege that, throughout the Class Period, iRobot reported double-digit revenue growth, which it attributed to increasing demand for its Roomba products, and expanded gross margin due to distributor acquisitions, greater brand awareness and technological innovation. Unbeknownst to investors, iRobot was engaging in channel-stuffing in order to inflate its sales and revenues figures, and had acquired two of its largest distributors in order to facilitate and conceal this deceptive practice.

On April 23, 2019, after the close of trading, iRobot announced that its quarterly revenues were below analyst expectations and revealed surging inventory levels. Specifically, iRobot reported days in inventory ("DII") of 140 for the three months ended March 30, 2019, compared to DII of 101 for the same period in the year prior. Inventory also rose to $181 million as of March 30, 2019, up from $112 million in April 2018. Following this news, the price of iRobot's stock fell $30.15 per share, or more than 23%, to close at $100.42 per share on April 24, 2019.

On July 23, 2019, after the close of trading, iRobot cut its full-year fiscal 2019 revenue guidance as well as its earnings per share guidance. Following this news, iRobot's stock price fell from $15.12 per share, or nearly 17%, to close at $74.51 per share on July 24, 2019.

On October 22, 2019, after the close of trading, iRobot reported its third quarter 2019 financial results and cut the high end of its revenue expectations for the year. iRobot said it rolled back price increases after a "suboptimal" customer response. In addition, iRobot reported increased inventory levels once again, with third quarter 2019 ending inventory of $248 million or 149 DII compared to the $161 million or 113 DII a year prior. Following this news, iRobot's stock price fell $4.97 per share, or 9.2%, to close at $49.06 per share on October 23, 2019.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation's top plaintiffs' law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms "representing the best qualities of the plaintiffs' bar and that demonstrated unusual dedication and creativity." Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm's "laser focus" and noting that our firm routinely finds itself "facing off against some of the largest and strongest defense law firms in the world." Benchmark Litigation has named Lieff Cabraser one of the "Top 10 Plaintiffs' Firms in America."

For more information about Lieff Cabraser and the firm's representation of investors, please visit https://www.lieffcabraser.com.

Follow us for updates on Twitter: https://twitter.com/LieffCabraser.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Source/Contact for Media Inquiries Only

Sharon M. Lee
Lieff Cabraser Heimann & Bernstein, LLP
Telephone: 1-800-541-7358

SOURCE: Lieff Cabraser Heimann & Bernstein

ReleaseID: 570860

VANCOUVER, BC / ACCESSWIRE / December 20, 2019 / GREAT ATLANTIC RESOURCES CORP. (TSXV:GR) (the "Company" or "Great Atlantic") is pleased to announce it has completed the 2019 exploration program at its Mascarene Property, located in southwest New Brunswick. The program consisted of prospecting and soil / rock geochemical sampling. The Mascarene Property is reported to contain multiple mineral occurrences with cobalt, copper, nickel, zinc, lead, gold and / or silver, some with historic workings. Initial 2019 rock samples from the west region of the property returned anomalous values including 0.16% zinc, 0.15% copper and 394 ppm vanadium (0.07% V2O5). Soil samples returned anomalous zinc values (up to 587 ppm Zn). More recent rock samples will be submitted for analysis.

Previous 2018 Great Atlantic rock samples from Mascarene include (News Release of October 17, 2018):

12.6% & 12.35% zinc, 4.34% lead & 41 g/t silver (rubble samples at historic Simpson workings).

5.02% copper & 2.0 g/t gold (rubble samples at historic Oliver – Oliver Cameron workings).

Historic pits / shafts are reported in multiple regions of the property dating back to the 1800s (New Brunswick. Dept. of Natural Resources and Energy Development Mineral Assessment Reports and Mineral Occurrence Database files). Sulfide bearing veins are reported at some of these sites. Great Atlantic located historic shallow pits and shafts in the east and west regions of the Mascarene Property during 2018.

A portion of the 2019 program was focused in the area of the historic Simpson Mine workings in the west region of the property, following up on results from the 2018 program. Sample highlights from the 2018 program in this area included 12.6 and 12.35% zinc, 4.34% lead and 41 g/t silver for rock samples and up to 855 ppm zinc for soil samples (News Release of October 17, 2018). Samples collected in this area during 2019 also returned anomalous values including 0.15% copper, 0.16% zinc and 0.08% lead for rock samples (float and rubble) and up to 587 ppm zinc and 161 ppm lead for soil samples. Of note, a rock grab sample from a mafic intrusive outcrop in this area returned 394 ppm vanadium (0.07% V2O5). These initial 2019 rock and soil samples were analyzed by ALS Canada Ltd. for gold by Fire Assay – Atomic Absorption (AA) and for 33 elements by four acid Inductively Coupled Plasma – Atomic Emission Spectroscopy (ICP-AES).

Historic shallow pit at Mascarene Property (historic Simpson Mine workings)

More recent 2019 program work focused on the northeast and east regions of the property with additional rock samples collected. These samples will also be submitted to ALS Canada Ltd. for gold and multi-element analysis. ALS Canada Ltd. is independent of Great Atlantic Resources Corp. The 2019 program was managed and conducted by a Qualified Person.

A 2002 airborne magnetic survey conducted by the New Brunswick government identified magnetic anomalies within the property. Great Atlantic management speculate these anomalies to be associated to a buried mafic intrusion(s). David Martin, VP Exploration for Great Atlantic states "the magnetic anomalies are a target for mafic intrusive hosted copper-nickel-cobalt deposits. Reported shallow vein-type mineralization at historic workings over magnetic anomalies may be indicative of deeper mafic intrusive hosted copper-cobalt-nickel mineralized bodies."

Readers are warned that historic data referred to in this News Release have not been verified by a qualified person.

Source: N.B. Dept. of Natural Resources and Energy Development Assessment Report No. 477530 (Stevens, 2013)

The Mascarene Property covers an area of approximately 2,080 hectares. The property is located approximately 6 kilometers southwest of the town of Saint George. Access is excellent with paved provincial roads transecting the property and within close proximity of the property.

David Martin, P.Geo., a Qualified Person as defined by NI 43-101 and VP Exploration for Great Atlantic, is responsible for the technical information contained in this News Release.

On Behalf of the board of directors

"Christopher R Anderson"

Mr. Christopher R. Anderson "Always be positive, strive for solutions, and never give up"

President CEO Director

604-488-3900 – Dir

Investor Relations:

Please call 604-488-3900

About Great Atlantic Resources Corp.: Great Atlantic Resources Corp. is a Canadian exploration company focused on the discovery and development of mineral assets in the resource-rich and sovereign risk-free realm of Atlantic Canada, one of the number one mining regions of the world. Great Atlantic is currently surging forward building the company utilizing a Project Generation model, with a special focus on the most critical elements on the planet that are prominent in Atlantic Canada, Antimony, Tungsten and Gold.

This press release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address future exploration drilling, exploration activities and events or developments that the Company expects, are forward looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include exploitation and exploration successes, continued availability of financing, and general economic, market or business conditions.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Great Atlantic Resource Corp
888 Dunsmuir Street – Suite 888, Vancouver, B.C., V6C 3K4

SOURCE: Great Atlantic Resources Corp.

ReleaseID: 570918

Dr. Bomi Joseph is the Director of Peak Health Center and a firm supporter of formal education. As a prominent healthcare professional, he understands the financial cost of attending a post-secondary institution and wishes to support individuals entering the medical field.

LOS GATOS, CA /ACCESSWIRE / December 20, 2019 / Dr. Bomi Joseph is proud to announce Alexandrea Neuwirth, as the winner of the Academic Scholarship Program and recipient of $1,500 USD.

As an experienced healthcare professional, Dr. Bomi Joseph wishes to support students currently pursuing a career in medicine by minimizing their financial burden.

Alexandrea Neuwirth is currently attending San Diego, Mesa College, and upon graduation aims to fulfill the academic requirements needed to be a certified physical therapist. Her personal health experiences have served as a continuous source of motivation and her long-term objective is to help others regain function through movement and exercise. She claims that receiving this scholarship will allow her to focus primarily on her classes, as opposed to financing her education.

Alexandrea is also a supporter of endo-health – a branch of medicine that seeks to discover natural alternatives to human health over traditional pharmaceutical drugs. As an admirer of Dr. Bomi Joseph, she wishes to discover innovative solutions to provide top quality care.

She looks forward to starting her career in medicine and identifying ways to foster positive change in her community.

Dr. Bomi Joseph would like to thank all of the applicants who took the time to apply and reminds them that they can reapply for the next quarter.

About Dr. Bomi Joseph

Dr. Bomi Joseph is an experienced healthcare professional and a strong proponent of endo-health or health from within. Having earned his Ph.D. from Ohio State University, Dr. Joseph has dedicated his career to discovering alternatives to traditional medicine and pharmaceutical drugs. As the Director of Peak Health Center, Dr. Bomi Joseph takes pride in providing all-natural solutions to improve human health.

For more information on Dr. Bomi Joseph please visit his website at https://www.drbomijoseph.com/

For further details on Peak Health Center visit https://peak.health/

Contact Information

Dr. Bomi Joseph

Phone: (844) 960-7325

Email: admin@peak.health

SOURCE: Dr. Bomi Joseph

ReleaseID: 570926

NEW YORK, NY / ACCESSWIRE / December 20, 2019 / All three marketing and public relations subsidiaries of Dolphin Entertainment (NASDAQ:DLPN), 42West, The Door, and Shore Fire Media, have earned spots on The Observer's prestigious PR Power 50, a widely-respected ranking of the 50 most influential public relations firms in the nation.

"Such prestigious third-party validation of the market-leading position of each of our subsidiaries serves as affirmation of our core strategy, that we are creating an entertainment marketing ‘Super Group,' the only one of its kind in our industry," said Bill O'Dowd, CEO of Dolphin Entertainment. "Our honorees represent the best in the business but, more importantly, they are agencies that have become critical partners for their clients during highly transformative times. Individually, each agency offers best-in-class service, and collectively, we enjoy unrivaled relationships and unique opportunities across the full breadth of entertainment and pop culture, for the benefit of individual and corporate clients alike."

42West (#4), led by Co-CEO's Leslee Dart, Amanda Lundberg and Allan Mayer, earned the highest-ranking of any entertainment firm, and was cited by the Observer for having "a banner year, representing 60+ movies; they included the year's two most inescapable films, Martin Scorsese's The Irishman and Fred Rogers biopic A Beautiful Day in the Neighborhood."

The Door (#18), led by Co-Founder/President Lois Najarian O'Neill and Co-Founder/CEO Charlie Dougiello, has now been ranked in the Top 20 firms for three consecutive years and was credited with signing many high-profile clients across its hospitality, travel and consumer products divisions, including Venmo and the Empire State Building as well as projects with HBO and Rachael Ray X Uber Eats. The Observer praised The Door's recent work saying "this endlessly creative firm keeps expanding the boundaries of PR."

Shore Fire Media (#49), led by CEO Marilyn Laverty, burst onto the rankings "with a long list of 2019 Grammy wins and a roster of platinum-plated clients like Bruce Springsteen, Carole King and Cyndi Lauper, Shore Fire topped the charts with hot podcasts (Freakonomics, Dolly Parton's America), acclaimed documentaries (Linda Ronstadt: The Sound of My Voice and Echo in the Canyon) and huge festivals like the Bud Light Super Bowl Music Fest (with, yes, Cardi B and Bruno Mars)."

About Dolphin Entertainment, Inc.

Dolphin Entertainment is a leading independent entertainment marketing and premium content development company. Through our subsidiaries 42West, The Door and Shore Fire Media, we provide expert strategic marketing and publicity services to many of the top brands, both individual and corporate, in the film, television, music and hospitality industries. Dolphin's acquisition of Viewpoint Creative adds full-service creative branding and production capabilities to our marketing group. Dolphin's legacy content production business, founded by Emmy-nominated CEO Bill O'Dowd, has produced multiple feature films and award-winning digital series.

About 42 West

With unparalleled experience, contacts, and expertise, 42West is one of the leading full-service public-relations firms in the entertainment industry. The firm's PR professionals have developed and executed marketing and publicity strategies for hundreds of movies, television shows, and digital productions as well as for countless individual actors, filmmakers, recording artists, and authors. In addition, 42West has also provided strategic communications counsel to a wide variety of high-profile individuals and corporate clients – ranging from movie and pop stars to major studios and media conglomerates.

About The Door

Founded in 2008, The Door is a creative relations agency with a focus on building important, viable brands through diverse initiatives. Headquartered in New York, with offices in Chicago, Los Angeles, Nashville and Miami – The Door represents a wide range of clients-including food and beverage, personalities, hospitality brands, events, consumer products, technology offerings, and entertainment/media entities.

About Shore Fire

Shore Fire represents artists and culture makers at the top of their fields. The company's dedicated teams in New York, Los Angeles, and Nashville wield extensive, varied expertise to strategically amplify narratives and shape reputations for career-advancing effect. Shore Fire Media represents top recording artists in multiple genres, songwriters, music producers, record labels, music industry businesses, venues, trade organizations, authors, comedians, social media personalities and cultural institutions.

Special Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements may address, among other things, Dolphin Entertainment's expected financial and operational results and the related assumptions underlying its expected results. These forward-looking statements are distinguished by the use of words such as "will," "would," "anticipate," "expect," "believe," "designed," "plan," or "intend," the negative of these terms, and similar references to future periods. These views involve risks and uncertainties that are difficult to predict and, accordingly, Dolphin Entertainment's actual results may differ materially from the results discussed in its forward-looking statements. Dolphin Entertainment's forward-looking statements contained herein speak only as of the date of this press release. Factors or events Dolphin Entertainment cannot predict, including those described in the risk factors contained in its filings with the Securities and Exchange Commission, may cause its actual results to differ from those expressed in forward-looking statements. Although Dolphin Entertainment believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be achieved, and Dolphin Entertainment undertakes no obligation to update publicly any forward-looking statements as a result of new information, future events, or otherwise, except as required by applicable law.

Contact:

James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com

SOURCE: Dolphin Entertainment, Inc.

ReleaseID: 570912

SAN FRANCISCO, CA / ACCESSWIRE / December 20, 2019 / The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action litigation on behalf of investors who purchased or otherwise acquired the securities of Under Armour, Inc., ("Under Armour" or the "Company") (NYSE:UA; UAA) between September 16, 2015 and November 1, 2019, inclusive (the "Class Period").

If you purchased or otherwise acquired the securities of Under Armour during the Class Period, you may move the Court for appointment as lead plaintiff by no later than January 6, 2020. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the actions.

Under Armour investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

Background on the Under Armour Securities Class Litigation

Under Armour, based in Baltimore, Maryland, develops, markets, and distributes branded performance apparel, footwear, and accessories for men, women, and youth.

The actions allege that during the Class Period, Under Armour made false and/or misleading statements and/or failed to disclose that: (i) Under Armour improperly shifted sales from quarter to quarter to keep pace with their long-running year-over-year 20% net revenue growth; (ii) the Company had been subject to federal accounting probes since at least July 2017; and (iii) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On November 3, 2019, The Wall Street Journal reported that the U.S. Department of Justice ("DOJ") and the Securities Exchange Commission ("SEC") are investigating whether Under Armour shifted sales from quarter to quarter to appear healthier. On the following day, Under Armour confirmed that it was under DOJ and SEC investigations and has been responding to requests for documents and information regarding certain of its accounting practices and related disclosures, beginning with submissions to the SEC in July 2017. Following this news, the price of Under Armour Class A common stock fell $4.00 per share, or nearly 18.9%, to close at $17.14 per share, and its Class C common stock fell $3.47 per share, or 18.3%, to close at $15.44 per share.

About Lieff Cabraser
Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation's top plaintiffs' law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms "representing the best qualities of the plaintiffs' bar and that demonstrated unusual dedication and creativity." Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm's "laser focus" and noting that our firm routinely finds itself "facing off against some of the largest and strongest defense law firms in the world." Benchmark Litigation has named Lieff Cabraser one of the "Top 10 Plaintiffs' Firms in America."

For more information about Lieff Cabraser and the firm's representation of investors, please visit https://www.lieffcabraser.com/.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Source/Contact for Media Inquiries Only
Sharon M. Lee
Lieff Cabraser Heimann & Bernstein, LLP
Telephone: 1-800-541-7358

SOURCE: Lieff Cabraser Heimann & Bernstein

ReleaseID: 570856

Presentation from Abstract to be Delivered at the Southern Association of Vascular Surgery Conference January 8 to 11 in Palm Beach, Florida

IRVINE, CA / ACCESSWIRE / December 20, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that an abstract entitled Results of First-in-Human Implantation of a Prosthetic Venous Valve has been published in the January 2020 edition of the Journal of Vascular Surgery®. A presentation from the abstract will be delivered by Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-man VenoValve study in Bogota, Colombia, at the 44th Annual Meeting of the Southern Association for Vascular Surgery ("SAVS"), which will take place January 8 to January 11 in Palm Beach, Florida.

Robert Berman, Hancock Jaffe's Chief Executive Officer stated, "We are proud of Dr. Marc Glickman, our Senior Vice President and Chief Medical Officer, as well as the rest of our medical team, for the worldwide attention we are receiving on our ground breaking work with the VenoValve. In addition to the honors mentioned above, the abstract from the Journal of Vascular Surgery was featured in a bi-weekly news update email sent out by the American College of Surgeons to its more than 82,000 members. Our success with the VenoValve continues to be of intense interest to the vascular and surgical communities."

Chronic Venous Insufficiency ("CVI") occurs when valves in the veins of the leg fail, causing blood to flow backwards (reflux) and pool in the lower extremities. The pooling of blood causes increased pressure in the veins of the leg, known as venous hypertension. CVI of the deep venous system is a debilitating condition that often includes leg swelling, debilitating pain, and in severe instances, open sores known as venous ulcers.

HJLI has implanted VenoValves in 10 CVI patients as part of its first-in-man trial in Colombia. On October 24, 2019, six-month data for the trial was presented on the first 5 patients that received VenoValves, which showed significant improvements in all study endpoints, minimal safety issues, and dramatic improvement and healing of venous ulcers.

Approximately 2.4 million people in the U.S. suffer from CVI due to reflux in the deep venous system. Estimates indicate that direct medical costs from CVI in the U.S. exceed $30 Billion per year. There are currently no FDA approved devices or effective treatments for deep venous CVI.

The Journal of Vascular Surgery® is dedicated to the science and art of vascular surgery, aiming to be the premier international journal of medical, endovascular and surgical care of vascular diseases. Since the first issue was released in 1984, the goal of the journal has been to improve the management of patients with vascular diseases by publishing relevant papers that report important medical, surgical and endovascular advances, test new hypotheses, and address current controversies.

The Southern Association of Vascular Surgery was established to promote the art and science of vascular surgery and to further education in the comprehensive care of vascular disease, including disorders of the arteries, veins, lymphatics and microcirculation exclusive of the heart and brain. The SAVS covers the regions of Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, South Carolina, Tennessee, Texas, Virginia, West Virginia and Washington D.C. The Association is widely considered among the most established and vibrant regional vascular organizations in the United States. The 44th Annual Meeting of the Southern Association of Vascular Surgery will be held January 8 – 11, 2020 at The Breakers Palm Beach in Palm Beach, Florida

About Hancock Jaffe Laboratories, Inc.

Hancock Jaffe Laboratories (NASDAQ:HJLI) specializes in developing and manufacturing bioprosthetic (tissue based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. Hancock Jaffe currently has two lead product candidates: the VenoValve®, a porcine based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency; and the CoreoGraft®, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery. Hancock Jaffe has a 20-year history of developing and producing FDA approved medical devices that sustain or support life. The current management team at Hancock Jaffe has been associated with over 80 FDA or CE marked medical devices. For more information, please visit HancockJaffe.com.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of Hancock Jaffe Laboratories, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the performance of the new board members described herein) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

HJLI Press Contacts:
Amy Carmer
Tel: 949-261-2900
Email: ACarmer@HancockJaffe.com

Media & Investor Relations Contact:
MZ North America
Chris Tyson
Managing Director
(949) 491-8235
HJLI@mzgroup.us
www.mzgroup.us

SOURCE: Hancock Jaffe Laboratories, Inc.

ReleaseID: 570889

MIAMI, FL / ACCESSWIRE / December 20, 2019 / GH Capital, Inc. (OTC PINK:GHHC), through its Vitana-X sunsidiary, a provider of comprehensive programs for greater well-being, fitness and health with a wellness network marketing program, today announced the launch of its VITApure line health an wellness products for its multi-level-marleting (MLM) program.

CBD-X Cannabidiol, Vitamin D3 and Curcumin products are all now available.

First and foremost is the patented Swiss micellelization process, which is the world's only proven method to make fat-soluble substances and vitamins water-soluble without resorting to polysorbates or other harmful ingredients. The process of micellelization normally takes place in the body and takes much longer than the natural excretory process, so only a fraction of the vital substances can be absorbed.

This unique process, which won the World Pharma Award in October 2018, guarantees a bioavailability of at least 95% that has never been achieved before. The average value for fat- soluble substances is normally between 10-20%.

VITANA X will provide the following supplements based on Micell-Technology: Cannabidiol (CBD) | Boswellia Serrata | Curcumin | Vitamin D3

This information is based on scientific evidence.

Vitamin D deficiency is one of the most common nutrient deficiencies. Overall, vitamin D deficiency is a silent epidemic. The symptoms are usually subtle and may take years or decades to surface. Vitamin D deficiency is associated with a variety of health issues, as well as reduced life expectancy.

Turmeric may be the most effective nutritional supplement in existence. Curcumin is the active ingredient in turmeric, and it has powerful biological properties. Curcumin is known for its anti-inflammatory, anti-tumor and antioxidant effects. Curcumin is a natural anti-inflammatory compound.

Scientists now believe that chronic, low-level inflammation plays a major role in almost every chronic, Western disease. This includes heart disease, cancer, metabolic syndrome, Alzheimer's and various degenerative conditions. Curcumin is strongly anti-inflammatory. In fact, it's so powerful that it matches the effectiveness of some anti-inflammatory drugs, without the side effects.

About GH Capital / Vitana-X

GH Capital, Inc.'s (OTC: GHHC) Vitana-X, an international wellness company specializing in the development and manufacture of health-promoting products based on DNA analysis. As a pioneer in this industry and a worldwide network of highly qualified experts, it offers its customers extensive opportunities to lead a healthier life. Vitana-X offers comprehensive programs for greater well-being, fitness and health by helping you achieve the desired results and offering exercises that fit your body type. Vitana-X wants to support people in their healthy development and be their reliable partner for their full potential. Vitana-X comes from two worlds and wants to unite them in the future – science and the challenges of daily life, so that its customers can continue to care for other areas of life without sacrificing a healthy life.

For additional information on Vitana-X, please visit: http://vitana-x.net.

Forward-Looking Statements

Forward-Looking Statements. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Form 10-K filed on December 28, 2018, for the fiscal year ended September 30, 2018, including but not limited to the discussion under "Risk Factors" therein, which the Company has filed with the SEC and which may be viewed at http://www.sec.gov.

Contact Information:

press@ghcapital-inc.us
305-714-9397

SOURCE: GH Capital, Inc.

ReleaseID: 570803

CLOVERDALE, CA / ACCESSWIRE / December 20, 2019 / Indo Global Exchange(s) Pte Ltd (OTC PINK:IGEX) is pleased to announce Leonard Armenta has been appointed as the company's CEO.

Effective immediately Mr. Armenta will take over all operations for Indo Global. The company believes that due to Mr. Armenta's vast experience in the sports nutrition industry and his personal knowledge of the acquisition target of Sinister Labs that he is best suited to bring the company's ambitions to fruition.

Stated outgoing CEO, Jason Black: "After careful consideration I believe the best path forward is to leave the company in the hands of Mr. Armenta. The Sinister acquisition was brought to the company by Leonard and he should be the one to see that it closes. I thank shareholders for their ongoing support during my time with IGEX and wish everyone the best into future."

Forward Looking Statements:

This press release contains forward-looking statements. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Some or all of the results anticipated by these forward-looking statements may not be achieved. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Contact:

Jason Black
igexotc@gmail.com

SOURCE: Indo Global Exchanges Pte Ltd

ReleaseID: 570925

First of two monthly graphite purchase orders to the value of US$ 6 Million as part of an aggregate US$25,000,000 deal spanning over 39 months payable in Toda Notes ("TDN")
The deal between TODAQ and Gratomic Inc. is powered by the TDN digital asset
Graphite to sit in TDN reserve backstop to underpin the true value of the digital asset

TORONTO, ON / ACCESSWIRE / December 20, 2019 / Gratomic Inc. ("Gratomic" or the "Company") (TSX-V:GRAT)(FRANKFURT:CB81) a vertically integrated graphite to graphenes, advanced materials development company announces it has received its first two purchase orders for a total of USD 6 Million following a previously announced supply agreement on October 17, 2019 (https://gratomic.ca/gratomic-signs-deal-to-supply-graphite-to-todaq/) for an aggregate of USD $25,000,000 of graphite in an all-digital-asset deal from TODAQ STAR Program Phase 1 Corp, a subsidiary of TODAQ Holdings. The purchase orders are each for 600 tonnes of graphite valued at USD $6,000,000 solely payable in TDN at a price of USD$0.10 per TDN for an aggregate of TDN 60,000,000 that is to be delivered within 90 days.

Subsequent to the success of the initial delivery, TODAQ will place one additional order of 600 tonnes of graphite with 30 day intervals bringing the total to 1800 tonnes of graphite for USD $9,000,000 in consideration for the issuance of an aggregate of 90 million TDN. Thereafter, TODAQ will place orders on a monthly basis with the value of USD $484,848.49 based on both the purchase price for graphite and the exchange between USD and TDN applicable at the time over a period of 39 months.

The agreement marks the first steps towards a significant journey for Sovereignty Tech pioneer TODAQ, with a strategic intention towards both building its TDN rewards program and allowing cryptographic ownership of commodities so that all business, people and markets can transact quickly with security and long-term stability. Furthermore, the graphite will sit in the TDN reserve backstop as part of a diverse set of commodities to underpin the true value of deployed TDN with physical substance and utility.

No mineral resources, let alone mineral reserves demonstrating economic viability and technical feasibility, have been delineated on the Aukam Property. The Company is not in a position to demonstrate or disclose any capital and/or operating costs that may be associated with satisfying the terms of the Todaq Supply Agreement.

Gratomic wishes to emphasize that Supply Agreement is conditional on Gratomic being able to bring the Aukam project into a production phase, and for any graphite being produced to meet certain technical and mineralization requirements.

Gratomic continues to move its business towards production and as part of its business plan, expects to obtain a National Instrument 43-101 Standards of Disclosure for Mineral Projects technical report to help it ascertain the economics of Aukam. Presently the Company uses its existing pilot processing facility to produce certain amounts of graphite concentrate from accumulated surface graphite.

Risk Factors

The Company advises that it has not based its production decision on even the existence of mineral resources let alone on a feasibility study of mineral reserves, demonstrating economic and technical viability, and, as a result, there may be an increased uncertainty of achieving any particular level of recovery of minerals or the cost of such recovery, including increased risks associated with developing a commercially mineable deposit.

The Supply Agreement provides that if Gratomic is unable to deliver graphite in accordance with the orders from Todaq, Todaq has the right to refuse to take any subsequent attempt to fulfil the order, terminate the agreement immediately, obtain substitute product from another supplier and recover from the Company any costs and expenses incurred in obtaining such substitute product or suing for damages under the contract.

Historically, such projects have a much higher risk of economic and technical failure. There is no guarantee that production will begin as anticipated or at all or that anticipated production costs will be achieved.

Failure to commence production would have a material adverse impact on the Company's ability to generate revenue and cash flow to fund operations. Failure to achieve the anticipated production costs would have a material adverse impact on the Company's cash flow and future profitability.

Steve Gray, P.Geo. has reviewed, prepared and approved the scientific and technical information in this press release and is Gratomic Inc's "Qualified Person" as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

About TODAQ

TODAQ serves businesses, financial institutions and governments, offering a true digital asset ownership management platform for secure and efficient settlement. Leveraging the TODA protocol, each asset maintains an immutable, sovereign record of ownership. TODAQ aims to enhance the right of ownership over digital assets through the use of cryptographic and legal techniques to replace intermediaries. In 2019, TODAQ officially launched the TODA Note (TDN) as a fungible digital payment and loyalty asset. To learn more about TODAQ and TDN, please visit https://todaq.net and https://tdn.network, questions should be directed to comms@todaqfinance.com.

About Gratomic Inc.

Gratomic is an advanced materials company focused on mine to market commercialization of graphite products most notably high value graphene based components for a range of mass market products. Gratomic is collaborating with a leading European manufacturer of graphenes to use Aukam graphite to manufacture graphene products for commercialization on an industrial scale. The company is listed on the TSX Venture Exchange under the symbol GRAT.

For more information: visit the website at www.gratomic.ca or contact:

Arno Brand, Co-CEO, +1 416-561-4095

E-mail inquiries: abrand@gratomic.ca

"Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

FORWARD LOOKING STATEMENTS: This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR in Canada (available at www.sedar.com).

SOURCE: Gratomic Inc.

ReleaseID: 570917